Saquinavir
- TRADE NAME: Invirase (Roche)
- INDICATIONS: Advanced HIV infection
- CLASS: Antiretroviral, CYP3A4 inhibitor, HIV-1 protease inhibitor
- HALF-LIFE: 12 hours
Abiraterone, Afatinib, Alprazolam, Amitriptyline, Amprenavir, Astemizole, Atazanavir, Atorvastatin, Avanafil, Brigatinib, Cabazitaxel, Cabozantinib, Calcifediol, Clindamycin, Clozapine, Copanlisib, Crizotinib, Darifenacin, Darunavir, Dasatinib, Delavirdine, Dihydroergotamine, Dronedarone, Efavirenz, Elbasvir & Grazoprevir, Eluxadoline, Eplerenone, Ergot derivatives, Erlotinib, Everolimus, Fentanyl, Fesoterodine, Flibanserin, Fluticasone Propionate, Itraconazole, Ixabepilone, Ketoconazole, Lapatinib, Levomepromazine, Lomitapide, Lopinavir, Maraviroc, Methysergide, Midazolam, Midostaurin, Mifepristone, Naldemedine, Nelfinavir, Neratinib, Olaparib, Omeprazole, Paclitaxel, Palbociclib, Pantoprazole, Pazopanib, Pentamidine, Phenytoin, Pimozide, Ponatinib, Quinine, Ribociclib, Rifampin, Rilpivirine, Ritonavir, Rivaroxaban, Romidepsin, Rosuvastatin, Ruxolitinib, Sildenafil, Simeprevir, Simvastatin, Solifenacin, Sonidegib, St John's Wort, Sunitinib, Tadalafil, Telithromycin, Temsirolimus, Ticagrelor, Tipranavir, Tolvaptan, Vardenafil, Vemurafenib, Viloxazine, Vorapaxar, Voriconazole
PREGNANCY CATEGORY: B
Protease inhibitors cause dyslipidemia which includes elevated triglycerides and cholesterol and redistribution of body fat centrally to produce the so-called 'protease paunch', breast enlargement, facial atrophy, and 'buffalo hump'
Please login to see the rest of this drug profile
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
